{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:53:26Z","timestamp":1783367606836,"version":"3.54.6"},"reference-count":243,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["VIH\/SAU\/0021\/2011"],"award-info":[{"award-number":["VIH\/SAU\/0021\/2011"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["PEst-C\/SAU\/LA0002\/2013"],"award-info":[{"award-number":["PEst-C\/SAU\/LA0002\/2013"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"North Portugal Regional Operational Programme","award":["SAESCTN-PIIC&DT\/2011"],"award-info":[{"award-number":["SAESCTN-PIIC&DT\/2011"]}]},{"name":"FCT","award":["SFRH\/BPD\/92934\/2013"],"award-info":[{"award-number":["SFRH\/BPD\/92934\/2013"]}]},{"name":"FCT","award":["SFRH\/BD\/96519\/2013"],"award-info":[{"award-number":["SFRH\/BD\/96519\/2013"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.addr.2016.01.017","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T00:16:08Z","timestamp":1454112968000},"page":"57-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Nanomedicine in the development of anti-HIV microbicides"],"prefix":"10.1016","volume":"103","author":[{"given":"Jos\u00e9","family":"das Neves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rute","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2016.01.017_bb0005","series-title":"AIDS by the Numbers","author":"UNAIDS","year":"2015"},{"key":"10.1016\/j.addr.2016.01.017_bb0010","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/QAD.0b013e328354622a","article-title":"The evolving epidemiology of HIV\/AIDS","volume":"26","author":"De Cock","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2016.01.017_bb0015","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2016.01.017_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/rmv.684","article-title":"HIV sexual transmission and microbicides","volume":"21","author":"Ari\u00ebn","year":"2011","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.addr.2016.01.017_bb0025","first-page":"13","article-title":"Microbicides for the prevention of sexually transmitted HIV infection","volume":"11","author":"Abdool Karim","year":"2013","journal-title":"Expert Rev. Anti-Infect. Ther."},{"issue":"Suppl. 4","key":"10.1016\/j.addr.2016.01.017_bb0030","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/01.aids.0000390706.81383.f3","article-title":"The last decade of microbicide clinical trials in Africa: from hypothesis to facts","volume":"24","author":"Ramjee","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2016.01.017_bb0035","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.addr.2016.01.017_bb0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0045","series-title":"CROI\u2014Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA","article-title":"FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women","author":"Rees","year":"2015"},{"key":"10.1016\/j.addr.2016.01.017_bb0050","author":"Microbicide Trials Network"},{"key":"10.1016\/j.addr.2016.01.017_bb0055","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMra0912273","article-title":"Nanomedicine","volume":"363","author":"Kim","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0060","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0065","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1039\/c2cs15344k","article-title":"Targeted polymeric therapeutic nanoparticles: design, development and clinical translation","volume":"41","author":"Kamaly","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb0070","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1101\/gad.226837.113","article-title":"Nanotechnology: emerging tools for biology and medicine","volume":"27","author":"Wong","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.addr.2016.01.017_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2013.04.035","article-title":"Nanopharmaceuticals for improved topical vaginal therapy: can they deliver?","volume":"50","author":"Vani\u0107","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.017_bb0080","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jconrel.2014.04.033","article-title":"Nanoparticle-based drug delivery to the vagina: a review","volume":"190","author":"Ensign","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.01.017_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425247.2014.924499","article-title":"Vaginal drug delivery: strategies and concerns in polymeric nanoparticle development","volume":"11","author":"Wong","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2016.01.017_bb0090","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.addr.2009.11.017","article-title":"Nanotechnology-based systems for the treatment and prevention of HIV\/AIDS","volume":"62","author":"das Neves","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb0095","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.addr.2009.11.022","article-title":"Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV\/AIDS","volume":"62","author":"du Toit","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/17425240903338055","article-title":"Nanoparticle-based vaginal drug delivery systems for HIV prevention","volume":"7","author":"Mallipeddi","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2016.01.017_bb0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/0974-777X.93764","article-title":"Nanotechnology applications to HIV vaccines and microbicides","volume":"4","author":"Boyapalle","year":"2012","journal-title":"J. Global Infect. Dis."},{"key":"10.1016\/j.addr.2016.01.017_bb0110","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1016\/j.biomaterials.2013.05.012","article-title":"A review of nanotechnological approaches for the prophylaxis of HIV\/AIDS","volume":"34","author":"Date","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2016.01.017_bb0115","series-title":"Drug Delivery and Development of Anti-HIV Microbicides","first-page":"415","article-title":"Nanotechnology-based systems for microbicide development","author":"Nunes","year":"2014"},{"key":"10.1016\/j.addr.2016.01.017_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.antiviral.2014.10.014","article-title":"Nanotech-derived topical microbicides for HIV prevention: the road to clinical development","volume":"113","author":"Sanchez-Rodriguez","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb0125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/rmv.1739","article-title":"Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis","volume":"23","author":"Nyamweya","year":"2013","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.addr.2016.01.017_bb0130","series-title":"HIV and the Pathogenesis of AIDS","author":"Levy","year":"2007"},{"key":"10.1016\/j.addr.2016.01.017_bb0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-med-080709-124959","article-title":"Early events in sexual transmission of HIV and SIV and opportunities for interventions","volume":"62","author":"Haase","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0140","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1462-5822.2012.01812.x","article-title":"The molecular basis of HIV entry","volume":"14","author":"Klasse","year":"2012","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.addr.2016.01.017_bb0145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrmicro1387","article-title":"Selective transmission of CCR5-utilizing HIV-1: the \u2018gatekeeper\u2019 problem resolved?","volume":"4","author":"Margolis","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2016.01.017_bb0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/74743","article-title":"Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract","volume":"6","author":"Collins","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0155","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cell.2007.10.014","article-title":"Semen-derived amyloid fibrils drastically enhance HIV infection","volume":"131","author":"M\u00fcnch","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.addr.2016.01.017_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009634","article-title":"Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides","volume":"6","author":"Zirafi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0165","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/aji.12231","article-title":"Role of semen in modulating the female genital tract microenvironment\u2014implications for HIV transmission","volume":"71","author":"Doncel","year":"2014","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.addr.2016.01.017_bb0170","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1021\/bm900344q","article-title":"Movements of HIV-virions in human cervical mucus","volume":"10","author":"Boukari","year":"2009","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2016.01.017_bb0175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/mi.2012.87","article-title":"Human cervicovaginal mucus contains an activity that hinders HIV-1 movement","volume":"6","author":"Shukair","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2016.01.017_bb0180","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2796.2007.01822.x","article-title":"Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women","volume":"262","author":"Hirbod","year":"2007","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0185","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0897.2007.00561.x","article-title":"Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense","volume":"59","author":"Cole","year":"2008","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.addr.2016.01.017_bb0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2334-5-79","article-title":"Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model","volume":"5","author":"Olmsted","year":"2005","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.addr.2016.01.017_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","article-title":"Barrier properties of mucus","volume":"61","author":"Cone","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb0200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","article-title":"A vaginal fluid simulant","volume":"59","author":"Owen","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2016.01.017_bb0205","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/jac\/dkt156","article-title":"Vaginal concentrations of lactic acid potently inactivate HIV","volume":"68","author":"Aldunate","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2016.01.017_bb0210","doi-asserted-by":"crossref","first-page":"11196","DOI":"10.1128\/JVI.01899-08","article-title":"Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus","volume":"83","author":"Lai","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2016.01.017_bb0215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bpj.2015.05.034","article-title":"Predicting first traversal times for virions and nanoparticles in mucus with slowed diffusion","volume":"109","author":"Erickson","year":"2015","journal-title":"Biophys. J."},{"key":"10.1016\/j.addr.2016.01.017_bb0220","series-title":"Mucus","first-page":"49","author":"Cone","year":"2005"},{"key":"10.1016\/j.addr.2016.01.017_bb0225","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2174\/157016207782418452","article-title":"Neutralizing antibodies in mucosal secretions: IgG or IgA?","volume":"5","author":"Alexander","year":"2007","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.addr.2016.01.017_bb0230","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.29.8.1035","article-title":"Measurement of gastrointestinal pH profiles in normal ambulant human subjects","volume":"29","author":"Evans","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.addr.2016.01.017_bb0235","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrmicro3309","article-title":"Adding new dimensions: towards an integrative understanding of HIV-1 spread","volume":"12","author":"Fackler","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2016.01.017_bb0240","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.immuni.2007.01.007","article-title":"Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1","volume":"26","author":"Hladik","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2016.01.017_bb0245","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature08757","article-title":"Targeting early infection to prevent HIV-1 mucosal transmission","volume":"464","author":"Haase","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.addr.2016.01.017_bb0250","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QAI.0b013e3181989870","article-title":"Depletion of CD4+ T cells in semen during HIV infection and their restoration following antiretroviral therapy","volume":"50","author":"Politch","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2016.01.017_bb0255","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI22812","article-title":"Dangerous liaisons at the virological synapse","volume":"114","author":"Piguet","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2016.01.017_bb0260","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0b013e32833424c8","article-title":"Targeting Trojan horse leukocytes for HIV prevention","volume":"24","author":"Anderson","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2016.01.017_bb0265","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm0202-150","article-title":"Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells","volume":"8","author":"Meng","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11904-009-0004-1","article-title":"HIV infection of the genital mucosa in women","volume":"6","author":"Hladik","year":"2009","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.addr.2016.01.017_bb0275","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1073\/pnas.142586899","article-title":"Transepithelial transport of HIV-1 by M cells is receptor-mediated","volume":"99","author":"Fotopoulos","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2016.01.017_bb0280","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1128\/JVI.79.9.5762-5773.2005","article-title":"Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa","volume":"79","author":"Gurney","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2016.01.017_bb0285","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ca.20167","article-title":"Numerical distribution of lymphoid nodules in the human sigmoid colon, rectosigmoidal junction, rectum, and anal canal","volume":"19","author":"Cameron","year":"2006","journal-title":"Clin. Anat."},{"key":"10.1016\/j.addr.2016.01.017_bb0290","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/ije\/dyq057","article-title":"HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention","volume":"39","author":"Baggaley","year":"2010","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.addr.2016.01.017_bb0295","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nri1706","article-title":"Perils at mucosal front lines for HIV and SIV and their hosts","volume":"5","author":"Haase","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2016.01.017_bb0300","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1126\/science.286.5443.1353","article-title":"Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells","volume":"286","author":"Zhang","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.addr.2016.01.017_bb0305","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2016.01.017_bb0310","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/(SICI)1521-4141(199904)29:04<1202::AID-IMMU1202>3.0.CO;2-O","article-title":"Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection","volume":"29","author":"Lapenta","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2016.01.017_bb0315","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mi.2007.1","article-title":"HIV infection and the gastrointestinal immune system","volume":"1","author":"Brenchley","year":"2008","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2016.01.017_bb0320","first-page":"859","article-title":"Dendritic-cell interactions with HIV: infection and viral dissemination","volume":"6","author":"Wu","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2016.01.017_bb0325","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0092-8674(00)80694-7","article-title":"DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells","volume":"100","author":"Geijtenbeek","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.addr.2016.01.017_bb0330","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/wnan.1315","article-title":"Nanomedical engineering: shaping future nanomedicines","volume":"7","author":"Luo","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2016.01.017_bb0335","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1039\/C1NJ20396G","article-title":"Dendrimers as topical microbicides with activity against HIV","volume":"36","author":"Jim\u00e9nez","year":"2012","journal-title":"New J. Chem."},{"key":"10.1016\/j.addr.2016.01.017_bb0340","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1477-3155-8-15","article-title":"PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture","volume":"8","author":"Lara","year":"2010","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2016.01.017_bb0345","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1477-3155-9-38","article-title":"Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins","volume":"9","author":"Lara","year":"2011","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2016.01.017_bb0350","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/B978-0-12-391858-1.00002-2","article-title":"Gold manno-glyconanoparticles for intervening in HIV gp120 carbohydrate-mediated processes","volume":"509","author":"Di Gianvincenzo","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2016.01.017_bb0355","doi-asserted-by":"crossref","first-page":"83013","DOI":"10.1039\/C5RA16353F","article-title":"In situ stabilized AgNPs and (Cu\u2013Cur) CD dispersed gel, a topical contraceptive antiretroviral (ARV) microbicide","volume":"5","author":"Gaurav","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.addr.2016.01.017_bb0360","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev.med.59.061206.112737","article-title":"Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission","volume":"59","author":"Klasse","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.addr.2014.12.004","article-title":"Polymer-based nanocarriers for vaginal drug delivery","volume":"92","author":"das Neves","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb0370","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.virol.2010.06.008","article-title":"Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV","volume":"405","author":"Caron","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.addr.2016.01.017_bb0375","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1142\/S1793984410000225","article-title":"Liposomal gels for vaginal delivery of the microbicide MC-1220: preparation and in vivo vaginal toxicity and pharmacokinetics","volume":"1","author":"Mourtas","year":"2010","journal-title":"Nano LIFE"},{"key":"10.1016\/j.addr.2016.01.017_bb0380","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3109\/03639045.2011.637048","article-title":"Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention","volume":"38","author":"Wang","year":"2012","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0385","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1002\/jps.22529","article-title":"Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention","volume":"100","author":"Alukda","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.017_bb0390","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb0395","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.2217\/nnm.15.160","article-title":"The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials","author":"Roy","year":"2015","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.addr.2016.01.017_bb0400","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3109\/03639045.2013.838581","article-title":"Production of pure indinavir free base nanoparticles by a supercritical anti-solvent (SAS) method","volume":"40","author":"Imperiale","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0405","series-title":"Advancing Prevention Technologies for Sexual and Reproductive Health: A Strategy Symposium, Berkeley, CA, USA","article-title":"Improving solubility of dapivirine by using nanotechnology","author":"Garg","year":"2009"},{"key":"10.1016\/j.addr.2016.01.017_bb0410","series-title":"ISPE Australasia Conference 2009, Sydney, Australia","article-title":"Application of nanotechnology to enhance the solubility of poorly water soluble drug dapivirine","author":"Gupta","year":"2009"},{"key":"10.1016\/j.addr.2016.01.017_bb0415","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1007\/s11095-012-0787-4","article-title":"Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles","volume":"29","author":"Prasad","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb0420","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1021\/bm4012425","article-title":"mPEG-PAMAM-G4 nucleic acid nanocomplexes: enhanced stability, RNase protection, and activity of splice switching oligomer and poly I:C RNA","volume":"14","author":"Reyes-Reveles","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2016.01.017_bb0425","series-title":"Mucosal Delivery of Biopharmaceuticals","first-page":"261","article-title":"Vaginal delivery of biopharmaceuticals","author":"das Neves","year":"2014"},{"key":"10.1016\/j.addr.2016.01.017_bb0430","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/QAI.0b013e31818c953f","article-title":"Chemokine analogues show suitable stability for development as microbicides","volume":"49","author":"Cerini","year":"2008","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2016.01.017_bb0435","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11095-008-9765-2","article-title":"Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles","volume":"26","author":"Ham","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb0440","doi-asserted-by":"crossref","first-page":"370308","DOI":"10.1155\/2011\/370308","article-title":"Modeling drug\u2013carrier interaction in the drug release from nanocarriers","volume":"2011","author":"Zeng","year":"2011","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.addr.2016.01.017_bb0445","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(11)60878-7","article-title":"Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women","volume":"378","author":"Abdool Karim","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2016.01.017_bb0450","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/nnm.13.136","article-title":"Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention","volume":"9","author":"Meng","year":"2014","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.addr.2016.01.017_bb0455","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2007.12.017","article-title":"A review of stimuli-responsive nanocarriers for drug and gene delivery","volume":"126","author":"Ganta","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.01.017_bb0460","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1369-7021(12)70195-5","article-title":"Intracellular drug release nanosystems","volume":"15","author":"Meng","year":"2012","journal-title":"Mater. Today"},{"key":"10.1016\/j.addr.2016.01.017_bb0465","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijpharm.2010.10.032","article-title":"pH-sensitive Eudragit nanoparticles for mucosal drug delivery","volume":"403","author":"Yoo","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0470","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ejpb.2011.06.007","article-title":"pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission","volume":"79","author":"Zhang","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0475","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2164\/jandrol.04104","article-title":"A review of the physical and chemical properties of human semen and the formulation of a semen simulant","volume":"26","author":"Owen","year":"2005","journal-title":"J. Androl."},{"key":"10.1016\/j.addr.2016.01.017_bb0480","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/humrep\/17.8.2112","article-title":"Semen alterations in HIV-1 infected men","volume":"17","author":"Dulioust","year":"2002","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.addr.2016.01.017_bb0485","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.biomaterials.2011.10.004","article-title":"Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery","volume":"33","author":"Huang","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2016.01.017_bb0490","series-title":"Mucoadhesive Materials and Drug Delivery Systems","first-page":"99","article-title":"Vaginal mucosa and drug delivery","author":"das Neves","year":"2014"},{"key":"10.1016\/j.addr.2016.01.017_bb0495","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1208\/s12248-013-9546-7","article-title":"Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV\/AIDS microbicide in vitro","volume":"16","author":"Agrahari","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2016.01.017_bb0500","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A","article-title":"Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: potential approach towards prevention of viral transmission","volume":"56","author":"Hayakawa","year":"1998","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.addr.2016.01.017_bb0505","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.bmcl.2010.03.079","article-title":"Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents","volume":"20","author":"Di Gianvincenzo","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2016.01.017_bb0510","doi-asserted-by":"crossref","first-page":"9874","DOI":"10.1002\/chem.200900923","article-title":"Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN","volume":"15","author":"Martinez-\u00c1vila","year":"2009","journal-title":"Chemistry"},{"key":"10.1016\/j.addr.2016.01.017_bb0515","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/cbic.200900294","article-title":"Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells","volume":"10","author":"Martinez-\u00c1vila","year":"2009","journal-title":"Chembiochem"},{"key":"10.1016\/j.addr.2016.01.017_bb0520","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/intimm\/dxs115","article-title":"Glycodendrimers prevent HIV transmission via DC-SIGN on dendritic cells","volume":"25","author":"Garcia-Vallejo","year":"2013","journal-title":"Int. Immunol."},{"key":"10.1016\/j.addr.2016.01.017_bb0525","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/AAC.01328-07","article-title":"Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides","volume":"52","author":"Lackman-Smith","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.01.017_bb0530","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.antiviral.2005.08.004","article-title":"Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses","volume":"68","author":"Gong","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb0535","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/03639040802488097","article-title":"Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action","volume":"35","author":"Mumper","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0540","first-page":"3255","article-title":"Engineered nanomaterial uptake and tissue distribution: from cell to organism","volume":"8","author":"Kettiger","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2016.01.017_bb0545","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1039\/C0CS00003E","article-title":"Strategies for the intracellular delivery of nanoparticles","volume":"40","author":"Chou","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb0550","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2010.11.019","article-title":"Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages","volume":"150","author":"Nowacek","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.01.017_bb0555","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s11095-011-0622-3","article-title":"Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine","volume":"29","author":"das Neves","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb0560","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/mp4002365","article-title":"In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine","volume":"10","author":"das Neves","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0565","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1021\/bc200663r","article-title":"Cellular uptake of gold nanoparticles bearing HIV gp120 oligomannosides","volume":"23","author":"Arnaiz","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2016.01.017_bb0570","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s11095-006-9101-7","article-title":"Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV\/AIDS","volume":"23","author":"Shah","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb0575","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/bit.21958","article-title":"A model predicting delivery of saquinavir in nanoparticles to human monocyte\/macrophage (Mo\/Mac) cells","volume":"101","author":"Ece Gamsiz","year":"2008","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2016.01.017_bb0580","doi-asserted-by":"crossref","first-page":"084803","DOI":"10.1063\/1.4926584","article-title":"Confocal fluorescence microscopy: an ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells","volume":"5","author":"Mandal","year":"2015","journal-title":"AIP Adv."},{"key":"10.1016\/j.addr.2016.01.017_bb0585","first-page":"2847","article-title":"Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4(+) immune cells","volume":"8","author":"Yang","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2016.01.017_bb0590","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(02)11079-8","article-title":"Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial","volume":"360","author":"Van Damme","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2016.01.017_bb0595","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMoa0707957","article-title":"Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission","volume":"359","author":"Van Damme","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0600","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/600867","article-title":"Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety","volume":"200","author":"Mesquita","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2016.01.017_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qai.0000159671.25950.74","article-title":"In vitro and in vivo: the story of nonoxynol 9","volume":"39","author":"Hillier","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2016.01.017_bb0610","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3851\/IMP2346","article-title":"Cytolytic nanoparticles attenuate HIV-1 infectivity","volume":"18","author":"Hood","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.addr.2016.01.017_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095411","article-title":"Nanoparticle incorporation of melittin reduces sperm and vaginal epithelium cytotoxicity","volume":"9","author":"Jallouk","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb0620","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.actbio.2015.02.007","article-title":"Precise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicides","volume":"18","author":"das Neves","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2016.01.017_bb0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061416","article-title":"Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis","volume":"8","author":"Chaowanachan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb0630","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1021\/acs.molpharmaceut.5b00544","article-title":"Nanoparticle-based ARV drug combinations for synergistic inhibition of cell-free and cell\u2013cell HIV transmission","volume":"12","author":"Jiang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0635","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/17425247.2011.586334","article-title":"Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale","volume":"8","author":"das Neves","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2016.01.017_bb0640","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.progpolymsci.2014.07.010","article-title":"Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review","volume":"39","author":"Sosnik","year":"2014","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.addr.2016.01.017_bb0645","doi-asserted-by":"crossref","first-page":"50393","DOI":"10.1074\/jbc.M309026200","article-title":"Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport","volume":"278","author":"Dawson","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2016.01.017_bb0650","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejpb.2014.02.006","article-title":"Mucoadhesive liposomes as new formulation for vaginal delivery of curcumin","volume":"87","author":"Berginc","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0655","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijpharm.2014.06.016","article-title":"Chitosan-coated liposomes for topical vaginal therapy: assuring localized drug effect","volume":"472","author":"J\u00f8raholmen","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0660","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejps.2011.06.007","article-title":"Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion","volume":"44","author":"Meng","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.017_bb0665","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb0670","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/adma.201201800","article-title":"Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery","volume":"24","author":"Ensign","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2016.01.017_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004294","article-title":"Altering mucus rheology to \u201csolidify\u201d human mucus at the nanoscale","volume":"4","author":"Lai","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb0680","article-title":"Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb0685","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/wnan.144","article-title":"Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?","volume":"3","author":"das Neves","year":"2011","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2016.01.017_bb0690","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2016.01.017_bb0695","doi-asserted-by":"crossref","first-page":"9726","DOI":"10.1002\/anie.200803526","article-title":"Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that \u201cslip\u201d through the human mucus barrier","volume":"47","author":"Wang","year":"2008","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.addr.2016.01.017_bb0700","doi-asserted-by":"crossref","first-page":"19268","DOI":"10.1073\/pnas.0905998106","article-title":"Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier","volume":"106","author":"Tang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2016.01.017_bb0705","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/anie.201006849","article-title":"Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus","volume":"50","author":"Yang","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.addr.2016.01.017_bb0710","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1073\/pnas.0911748107","article-title":"Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses","volume":"107","author":"Lai","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2016.01.017_bb0715","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/la4029035","article-title":"On the role of specific interactions in the diffusion of nanoparticles in aqueous polymer solutions","volume":"30","author":"Mun","year":"2014","journal-title":"Langmuir"},{"key":"10.1016\/j.addr.2016.01.017_bb0720","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1021\/mp8001254","article-title":"Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus","volume":"6","author":"Cu","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0725","doi-asserted-by":"crossref","first-page":"13671","DOI":"10.1039\/C5NR03178H","article-title":"POZylation: a new approach to enhance nanoparticle diffusion through mucosal barriers","volume":"7","author":"Mansfield","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2016.01.017_bb0730","first-page":"5383","article-title":"Spray-dried powders enhance vaginal siRNA delivery by potentially modulating the mucus molecular sieve structure","volume":"10","author":"Wu","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2016.01.017_bb0735","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejpb.2015.01.022","article-title":"Nano-carrier systems: strategies to overcome the mucus gel barrier","volume":"96","author":"D\u00fcnnhaupt","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0740","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nmat2444","article-title":"Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA","volume":"8","author":"Woodrow","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2016.01.017_bb0745","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jconrel.2011.06.036","article-title":"In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery","volume":"156","author":"Cu","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.01.017_bb0750","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003453","article-title":"Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus","volume":"4","author":"Ensign","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2016.01.017_bb0755","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1016\/j.biomaterials.2013.05.039","article-title":"Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake","volume":"34","author":"Ensign","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2016.01.017_bb0760","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/adhm.201300519","article-title":"Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth","volume":"3","author":"Yang","year":"2014","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.addr.2016.01.017_bb0765","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2016.01.017_bb0770","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1166\/jbn.2011.1194","article-title":"Biodegradable nanoparticles in the murine vagina: trans-cervical retrograde transport and induction of proinflammatory cytokines","volume":"7","author":"Malik","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2016.01.017_bb0775","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051995","article-title":"Nanoparticle transport from mouse vagina to adjacent lymph nodes","volume":"7","author":"Ballou","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb0780","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/aji.12409","article-title":"Effect of mucosal cytokine administration on selective expansion of vaginal dendritic cells to support nanoparticle transport","volume":"74","author":"Ramanathan","year":"2015","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.addr.2016.01.017_bb0785","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/infdis\/jir841","article-title":"Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse","volume":"205","author":"Louissaint","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2016.01.017_bb0790","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1089\/aid.2013.0122","article-title":"Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)\/pharmacodynamics (PD) in HIV prevention","volume":"29","author":"Romano","year":"2013","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.addr.2016.01.017_bb0795","doi-asserted-by":"crossref","first-page":"9835","DOI":"10.1073\/pnas.0711813105","article-title":"The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics","volume":"105","author":"Wilson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2016.01.017_bb0800","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jcph.292","article-title":"Topical microbicides and HIV prevention in the female genital tract","volume":"54","author":"Cottrell","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2016.01.017_bb0805","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/infdis\/jiu026","article-title":"Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial","volume":"209","author":"Wei","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2016.01.017_bb0810","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/mp050023q","article-title":"Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention","volume":"2","author":"McCarthy","year":"2005","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0815","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012309","article-title":"Structure activity relationship of dendrimer microbicides with dual action antiviral activity","volume":"5","author":"Tyssen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb0820","first-page":"561","article-title":"VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection","volume":"2","author":"Rupp","year":"2007","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2016.01.017_bb0825","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.03.186","article-title":"Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1","volume":"90","author":"Telwatte","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb0830","doi-asserted-by":"crossref","first-page":"18628","DOI":"10.1039\/C5NR04632G","article-title":"The SPL7013 dendrimer destabilizes the HIV-1 gp120-CD4 complex","volume":"7","author":"Nandy","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2016.01.017_bb0835","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1128\/AAC.48.10.3834-3844.2004","article-title":"In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission","volume":"48","author":"Dezzutti","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.01.017_bb0840","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1128\/AAC.01129-06","article-title":"Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture","volume":"51","author":"Cummins","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.01.017_bb0845","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1128\/AAC.50.5.1696-1700.2006","article-title":"Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model","volume":"50","author":"Patton","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.01.017_bb0850","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/aid.2005.21.207","article-title":"SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques","volume":"21","author":"Jiang","year":"2005","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.addr.2016.01.017_bb0855","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1128\/AAC.47.12.3784-3788.2003","article-title":"Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes","volume":"47","author":"Bernstein","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.01.017_bb0860","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/OLQ.0b013e3181bc0aac","article-title":"Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study","volume":"37","author":"O'Loughlin","year":"2010","journal-title":"Sex. Transm. Dis."},{"key":"10.1016\/j.addr.2016.01.017_bb0865","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/QAD.0b013e328346bd3e","article-title":"Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)","volume":"25","author":"McGowan","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2016.01.017_bb0870","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024095","article-title":"SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans","volume":"6","author":"Price","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb0875","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016258","article-title":"A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel(R)) in healthy young women administered twice daily for 14days","volume":"6","author":"Cohen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb0880","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/QAI.0b013e31823f2aeb","article-title":"Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety","volume":"59","author":"Moscicki","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2016.01.017_bb0885","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s10461-011-0028-6","article-title":"\u201cTell Juliana\u201d: acceptability of the candidate microbicide VivaGel(R) and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study","volume":"16","author":"Carballo-Dieguez","year":"2012","journal-title":"AIDS Behav."},{"key":"10.1016\/j.addr.2016.01.017_bb0890","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QAI.0b013e318198a7e6","article-title":"A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis","volume":"50","author":"Chen","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2016.01.017_bb0895","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1071\/SH07093","article-title":"Attitudes of men in an Australian male tolerance study towards microbicide use","volume":"5","author":"Holmes","year":"2008","journal-title":"Sex. Health"},{"key":"10.1016\/j.addr.2016.01.017_bb0900","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/wnan.1181","article-title":"Dendrimers\u2014revolutionary drugs for infectious diseases","volume":"4","author":"Lazniewska","year":"2012","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2016.01.017_bb0905","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jconrel.2012.04.050","article-title":"Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile","volume":"161","author":"Chonco","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.01.017_bb0910","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pola.27090","article-title":"Synthesis of anionic carbosilane dendrimers via \u201cclick chemistry\u201d and their antiviral properties against HIV","volume":"52","author":"Arn\u00e1iz","year":"2014","journal-title":"J. Polym. Sci. A Polym. Chem."},{"key":"10.1016\/j.addr.2016.01.017_bb0915","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1039\/c4ob00162a","article-title":"Synthesis of new anionic carbosilane dendrimers via thiol-ene chemistry and their antiviral behaviour","volume":"12","author":"Gal\u00e1n","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.addr.2016.01.017_bb0920","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/QAD.0b013e32835f2b7a","article-title":"Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission","volume":"27","author":"Vacas C\u00f3rdoba","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2016.01.017_bb0925","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1039\/C5NR03644E","article-title":"Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides","volume":"7","author":"Briz","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2016.01.017_bb0930","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2217\/nnm.14.79","article-title":"Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission","volume":"10","author":"Sep\u00falveda-Crespo","year":"2015","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.addr.2016.01.017_bb0935","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1166\/jbn.2015.2109","article-title":"Anti-human immunodeficiency virus activity of thiol-ene carbosilane dendrimers and their potential development as a topical microbicide","volume":"11","author":"S\u00e1nchez-Rodr\u00edguez","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2016.01.017_bb0940","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1097\/QAD.0b013e328361fa4a","article-title":"Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro","volume":"27","author":"C\u00f3rdoba","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2016.01.017_bb0945","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nano.2013.10.002","article-title":"Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide","volume":"10","author":"Sep\u00falveda-Crespo","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2016.01.017_bb0950","first-page":"3591","article-title":"Enhanced activity of carbosilane dendrimers against HIV when combined with reverse transcriptase inhibitor drugs: searching for more potent microbicides","volume":"9","author":"Vacas-C\u00f3rdoba","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2016.01.017_bb0955","doi-asserted-by":"crossref","first-page":"12733","DOI":"10.1039\/c2dt31099f","article-title":"Synthesis, structure and molecular modelling of anionic carbosilane dendrimers","volume":"41","author":"Rasines","year":"2012","journal-title":"Dalton Trans."},{"key":"10.1016\/j.addr.2016.01.017_bb0960","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.nano.2015.04.013","article-title":"Prevention vaginally of HIV-1 transmission in humanized BLT mice and mode of antiviral action of polyanionic carbosilane dendrimer G2-S16","volume":"11","author":"Sep\u00falveda-Crespo","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2016.01.017_bb0965","article-title":"Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing","author":"das Neves","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb0970","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpba.2010.01.007","article-title":"Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles","volume":"52","author":"das Neves","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2016.01.017_bb0975","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1021\/mp300408m","article-title":"Interactions of microbicide nanoparticles with a simulated vaginal fluid","volume":"9","author":"das Neves","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0980","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2012.10.034","article-title":"Development and validation of a HPLC method for the assay of dapivirine in cell-based and tissue permeability experiments","volume":"911","author":"das Neves","year":"2012","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.addr.2016.01.017_bb0985","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijpharm.2013.08.049","article-title":"Assessing the physical\u2013chemical properties and stability of dapivirine-loaded polymeric nanoparticles","volume":"456","author":"das Neves","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb0990","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s11095-013-1287-x","article-title":"Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice","volume":"31","author":"das Neves","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb0995","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1097\/00002030-200111230-00003","article-title":"Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides","volume":"15","author":"Di Fabio","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2016.01.017_bb1000","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials","volume":"27","author":"Cohen","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2016.01.017_bb1005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/clpt.2014.118","article-title":"A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis","volume":"96","author":"Jackson","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2016.01.017_bb1010","article-title":"Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission","volume":"11","author":"Kovarova","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2016.01.017_bb1015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.antiviral.2012.09.015","article-title":"Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis","volume":"96","author":"Date","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb1020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1166\/jbn.2015.1942","article-title":"Thermosensitive gel containing cellulose acetate phthalate-efavirenz combination nanoparticles for prevention of HIV-1 infection","volume":"11","author":"Date","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2016.01.017_bb1025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejps.2012.02.003","article-title":"Development of liposome gel based formulations for intravaginal delivery of the recombinant HIV-1 envelope protein CN54gp140","volume":"46","author":"Gupta","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.017_bb1030","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3109\/03639045.2012.707204","article-title":"Mucoadhesive nanoliposomal formulation for vaginal delivery of an antifungal","volume":"39","author":"Karimunnisa","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb1035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/08982104.2013.826242","article-title":"Novel vaginal drug delivery system: deformable propylene glycol liposomes-in-hydrogel","volume":"24","author":"Vani\u0107","year":"2014","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.addr.2016.01.017_bb1040","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.1021\/acs.chemrev.5b00046","article-title":"New developments in liposomal drug delivery","volume":"115","author":"Pattni","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2016.01.017_bb1045","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1128\/AAC.50.4.1497-1509.2006","article-title":"Preclinical evaluation of synthetic \u22122 RANTES as a candidate vaginal microbicide to target CCR5","volume":"50","author":"Kish-Catalone","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.01.017_bb1050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/aid.2006.0076","article-title":"Evaluation of \u22122 RANTES vaginal microbicide formulations in a nonhuman primate simian\/human immunodeficiency virus (SHIV) challenge model","volume":"23","author":"Kish-Catalone","year":"2007","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.addr.2016.01.017_bb1055","first-page":"1","article-title":"Advances in Novasome technology\u2014a review","volume":"5","author":"Agarwal","year":"2013","journal-title":"Int. J. App. Pharm."},{"issue":"Pt 12","key":"10.1016\/j.addr.2016.01.017_bb1060","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1099\/0022-1317-71-12-2899","article-title":"Liposomes modulate human immunodeficiency virus infectivity","volume":"71","author":"Konopka","year":"1990","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.addr.2016.01.017_bb1065","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1016\/j.biomaterials.2011.07.068","article-title":"Liposomes for HIV prophylaxis","volume":"32","author":"Malavia","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2016.01.017_bb1070","doi-asserted-by":"crossref","first-page":"125087","DOI":"10.1155\/2014\/125087","article-title":"Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV","volume":"2014","author":"Wheeler","year":"2014","journal-title":"Infect. Dis. Obstet. Gynecol."},{"key":"10.1016\/j.addr.2016.01.017_bb1075","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1172\/JCI45876","article-title":"Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras","volume":"121","author":"Wheeler","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2016.01.017_bb1080","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/mt.2013.77","article-title":"Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras","volume":"21","author":"Wheeler","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2016.01.017_bb1085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2012.12.023","article-title":"Advancements in the field of intravaginal siRNA delivery","volume":"167","author":"Yang","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.01.017_bb1090","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2016.01.017_bb1095","doi-asserted-by":"crossref","DOI":"10.4081\/idr.2011.2370","article-title":"Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants","volume":"3","author":"Eszterhas","year":"2011","journal-title":"Infect. Dis. Rep."},{"key":"10.1016\/j.addr.2016.01.017_bb1100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135288","article-title":"A multiple siRNA-based anti-HIV\/SHIV microbicide shows protection in both in vitro and in vivo models","volume":"10","author":"Boyapalle","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb1105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/pat.1813","article-title":"Biomedical applications of nanofibers","volume":"22","author":"Leung","year":"2011","journal-title":"Polym. Adv. Tech."},{"key":"10.1016\/j.addr.2016.01.017_bb1110","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.drudis.2014.10.018","article-title":"Cell-laden microfibers for bottom-up tissue engineering","volume":"20","author":"Onoe","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"Suppl.","key":"10.1016\/j.addr.2016.01.017_bb1115","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.antiviral.2013.09.022","article-title":"Electrospun fibers for vaginal anti-HIV drug delivery","volume":"100","author":"Blakney","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb1120","series-title":"Drug Delivery and Development of Anti-HIV Microbicides","first-page":"459","article-title":"Electrospun fibers for microbicide drug delivery","author":"Ball","year":"2014"},{"key":"10.1016\/j.addr.2016.01.017_bb1125","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/pat.3310","article-title":"Electrospun polystyrene fibers for HIV entrapment","volume":"25","author":"Huang","year":"2014","journal-title":"Polym. Adv. Tech."},{"key":"10.1016\/j.addr.2016.01.017_bb1130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049792","article-title":"Drug-eluting fibers for HIV-1 inhibition and contraception","volume":"7","author":"Ball","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb1135","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1128\/AAC.02564-14","article-title":"Electrospun solid dispersions of maraviroc for rapid intravaginal preexposure prophylaxis of HIV","volume":"58","author":"Ball","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.01.017_bb1140","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2147\/IJN.S61664","article-title":"Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures","volume":"9","author":"Blakney","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2016.01.017_bb1145","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2014.08.039","article-title":"Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery","volume":"475","author":"Krogstad","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.01.017_bb1150","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tim.2015.02.006","article-title":"Multipurpose prevention technologies: the future of HIV and STI protection","volume":"23","author":"Fern\u00e1ndez-Romero","year":"2015","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.addr.2016.01.017_bb1155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11095-015-1769-0","article-title":"Tunable release of multiclass anti-HIV drugs that are water-soluble and loaded at high drug content in polyester blended electrospun fibers","volume":"33","author":"Carson","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.017_bb1160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023243","article-title":"First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy","volume":"6","author":"Anton","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb1165","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1089\/aid.2012.0262","article-title":"RMP-02\/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic and pharmacodynamic study of tenofovir 1% gel compared to oral tenofovir disoproxil fumarate","volume":"28","author":"Anton","year":"2012","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.addr.2016.01.017_bb1170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125363","article-title":"A phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of tenofovir 1% gel (the CHARM-01 study)","volume":"10","author":"McGowan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2016.01.017_bb1175","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1089\/aid.2015.0098","article-title":"A phase 1 randomized, blinded comparison of the pharmacokinetics and colonic distribution of three candidate rectal microbicide formulations of tenofovir 1% gel with simulated unprotected sex (CHARM-02)","volume":"31","author":"Hiruy","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.addr.2016.01.017_bb1180","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jconrel.2014.09.013","article-title":"J. das Neves, Formulation and delivery of anti-HIV rectal microbicides: advances and challenges","volume":"194","author":"Nunes","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.01.017_bb1185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4155\/tde.11.139","article-title":"Nanosystem formulations for rectal microbicides: a call for more research","volume":"3","author":"Sarmento","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2016.01.017_bb1190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.clpt.6100236","article-title":"Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates","volume":"83","author":"Hendrix","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2016.01.017_bb1195","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1365-2125.2012.04267.x","article-title":"Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging","volume":"74","author":"Cao","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2016.01.017_bb1200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QAI.0b013e3182373b5e","article-title":"Distribution of cell-free and cell-associated HIV surrogates in the colon following simulated receptive anal intercourse in men who have sex with men","volume":"59","author":"Louissaint","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2016.01.017_bb1205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2014.10.026","article-title":"Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse","volume":"197","author":"Maisel","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.01.017_bb1210","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1086\/462424","article-title":"A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection","volume":"192","author":"Abner","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2016.01.017_bb1215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13346-015-0269-4","article-title":"Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates-proof of concept for HIV mucosal pre-exposure prophylaxis","volume":"6","author":"Samizadeh","year":"2016","journal-title":"Drug Deliv. Transl. Res."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X16300369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X16300369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:40:39Z","timestamp":1759207239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X16300369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":243,"alternative-id":["S0169409X16300369"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2016.01.017","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanomedicine in the development of anti-HIV microbicides","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2016.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}